ARTICLE | Clinical News
Gemesis bercaplermin regulatory update
January 9, 2012 8:00 AM UTC
BioMimetic said GEM 21S received CE Mark approval in the EU to treat osseous defects resulting from tooth extraction and trauma and for use in compromised patients where poor healing may occur. The ap...